Acevedo K, Aguilar-Pacheco PE, Arellano-Montaño S, Bastidas-Adrián MY, Domínguez B, García AR, Gómez-Martínez G, González-Estrada J, Hernández Á, Hidalgo L, Jervis P, Luna-Ceballos RI, Maya-Luna ML, Mercado M, Vidrio M, Padilla-Retana JA, Portocarrero L, Rangel-Sánchez G, Reza-Albarrán A, Rivera AJ, Trujillo-Lozoya C, Uribe AM, Velázquez FJ, Vergara A

Language: Spanish
References: 10
Page: 176-180
PDF size: 240.57 Kb.

ABSTRACT

Background: Acromegaly is a disease of low prevalence, with an incompletely defined epidemiology. Objective: To inform the first set of results of the National Acromegaly Registry, or «Epiacro» program. Design and methodology: The data base included clinical, biochemical, imaging, therapeutic and outcome information. Eighteen centres spread through out the Country participated in the study, registering patients diagnosed after 1990. Results: To date, 1,328 patients have been registered, of whom 60% are women. Mean age is 41.6 ± 12 years. Global prevalence was 13 cases per million, whereas the regional prevalence ranged from 7 to 49 cases per million. The most commonly reported symptoms were acral enlargement, headache, arthralgia, fatigue, hyperhydrosis and snoring. In almost half of the patients, an abnormality in glucose metabolism was found, one third had frank diabetes and another third had hypertension. In over 80% of cases a basal GH level was available, whereas in close to 60% the biochemical diagnosis was based on either a post-glucose GH and/or an IGF-1 level. In 70%, imaging studies revealed a non-invasive macroadenoma. Pituitary surgery was the most frequently used treatment, and over 40% required pharmacological treatment, usually with somatostatin analogs. Conclusion: In this first report of «Epiacro» we found a slightly lower disease prevalence than that reported in other parts of the World, a fact that highlights an important degree of under diagnosis.

REFERENCES

1. Melmed S. Acromegaly. N Engl J Med 2006; 355: 2558-2573.

2. Melmed S. Acromegaly: Pathogenesis and treatment. J Clin Invest 2009; 119: 3189-3200.

3. Mercado M, Espinosa de los Monteros AL, Sosa E et al. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease. Horm Res 2004; 62: 293-299.

4. Espinosa de los Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities of glucose metabolism. Pituitary 2010, Published Ahead of Print Dec 16.

5. Dekkers OM, Biermasz NR, Pereira AM, Romjin JA, Vandenbroucke JP. Mortality in acromegaly: a meta-analyisis. J Clin Endocrinol Metab 2008; 93: 61-67.

6. Mestron A, Webb SM, Astorga R et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 2004; 151: 439-446.

7. Bex M, Abs R, T’Sjoen G et al. AcroBel-the Belgian registry on acromegaly: a survey of the “real-life” outcome in 418 acromegalic subjects. Eur J Endocrinol 2007; 157: 399-409.

8. Petersenn S, Buchfelder M, Reincke M et al. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur J Endocrinol 2008; 159: 525-532.

9. Arellano S, Aguilar P, Dominguez B., Espinosa de los Monteros AL, González B, Sosa E, Mercado M et al. Segundo Consenso Nacional de Acromegalia: Recomendaciones para su diagnóstico, tratamiento y seguimiento. Revista de Endocrinología y Nutrición 2007; 15: S7-S16.

10. González B, Vargas G, Espinosa de los Monteros AL, Sosa E, Mercado M. Efficacy and safety of radiotherapy in a acromegaly. Arch Med Res 2011; 42: 48-52.